BioLineRx and Hemispherian to present GLIX1 data at EANO 2026

BioLineRx Ltd. and Hemispherian AS announced on September 10, 2026 that two abstracts on GLIX1 have been accepted at the 21st Meeting of the European Association of Neuro-Oncology, with one chosen for oral presentation on preclinical efficacy in orthotopic glioblastoma models, set for September 24-27 in Rome, Italy.¹

BioLineRx CEO Philip Serlin said the preclinical data show potent anti-tumor effects across in-vivo studies, and that an accompanying e-poster will describe the ongoing Phase 1/2a trial, which he said is actively enrolling patients¹.

In the preclinical work, oral GLIX1 dosed from 75 mg/kg once daily up to 1000 mg/kg twice daily produced dose-dependent tumor growth inhibition and survival benefit in two orthotopic GBM xenograft models, with antitumor activity seen even at the lowest dose tested.¹ Brain drug exposure reached 68-85% of plasma levels in mice, supporting central nervous system penetration.¹

The ongoing first-in-human study, an open-label, multicenter trial using a BOIN design, is escalating doses across up to 5 levels in as many as 30 patients with WHO grade 3/4 glioma who have had no more than two prior lines of therapy.¹ The trial's main goals are assessing safety, tolerability, and the maximum tolerated or recommended Phase 2 dose, while secondary measures cover pharmacokinetics, tumor response, and six-month progression-free survival, alongside exploratory biomarkers.¹ Four U.S. academic centers are enrolling patients.¹

The release also notes BioLineRx's approved product, APHEXDA (motixafortide), which is approved in the U.S. for stem cell mobilization ahead of autologous transplant in multiple myeloma, with commercial rights held by Ayrmid Ltd. outside Asia and Auspex Biosciences within Asia.¹